Sereti I, Dunham RM, Spritzler J et al.; ACTG 5214 Study Team. Blood 2009;113:6304–14.
In this randomized, placebo-controlled, dose-ranging clinical trial of single-dose subcutaneous injection of interleukin-7 administered to 11 patients with HIV on highly active antiretroviral therapy, the investigators found few adverse events and a potentially favorable increase in circulating CD4+ and CD8+ cells of central memory phenotype.
Interleukin-7 (IL-7) plays a prominent role in thymopoiesis and in the maturation and survival of T cells. It is produced throughout the body by epithelial, stromal, and endothelial cells and is elevated, possibly as a compensatory homeostatic response, in advanced HIV infection in association with CD4+ T-cell counts <200 cells/µL and other lymphopenias.